Anhedonia is associated with a specific depression profile and poor antidepressant response.

IF 4.5 2区医学 Q1 CLINICAL NEUROLOGY

International Journal of Neuropsychopharmacology Pub Date : 2024-11-10 DOI:10.1093/ijnp/pyae055

Antonina Luca, Maria Luca, Siegfried Kasper, Basilio Pecorino, Joseph Zohar, Daniel Souery, Stuart Montgomery, Panagiotis Ferentinos, Dan Rujescu, Antonino Messina, Raffaella Zanardi, Raffaele Ferri, Mariangela Tripodi, Bernhard T Baune, Giuseppe Fanelli, Chiara Fabbri, Julien Mendlewicz, Alessandro Serretti

{"title":"Anhedonia is associated with a specific depression profile and poor antidepressant response.","authors":"Antonina Luca, Maria Luca, Siegfried Kasper, Basilio Pecorino, Joseph Zohar, Daniel Souery, Stuart Montgomery, Panagiotis Ferentinos, Dan Rujescu, Antonino Messina, Raffaella Zanardi, Raffaele Ferri, Mariangela Tripodi, Bernhard T Baune, Giuseppe Fanelli, Chiara Fabbri, Julien Mendlewicz, Alessandro Serretti","doi":"10.1093/ijnp/pyae055","DOIUrl":null,"url":null,"abstract":"Background: Anhedonic features within major depressive disorder (MDD) have been associated with worse course and outcome and may predict non-response to treatment. However a detailed clinical profile of anhedonia in MDD is still lacking.Materials and methods: One thousand two hundred ninety-four patients with MDD were selected from the cross-sectional European multicenter Group for the Study of Resistant Depression (GSRD) study. Anhedonia was assessed through the Montgomery-Åsberg Depression Rating Scale anhedonia item \"inability to feel\". Clinical and demographic features were then analyzed.Results: The presence of anhedonia related to a distinct demographical (living alone) and clinical profile (thyroid diseases, diabetes, suicide risk, high number of previous depressive episodes, more severe MDD and more frequent inpatients status). Furthermore, anhedonia was associated with non-response to treatment and treatment resistance, even after adjusting for confounding variables.Conclusion: Our findings support the role of anhedonia as a modulating feature of MDD, being associated with a more severe depression profile. Moreover, anhedonic features are independent predictors of poor treatment response.","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ijnp/pyae055","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Anhedonic features within major depressive disorder (MDD) have been associated with worse course and outcome and may predict non-response to treatment. However a detailed clinical profile of anhedonia in MDD is still lacking.

Materials and methods: One thousand two hundred ninety-four patients with MDD were selected from the cross-sectional European multicenter Group for the Study of Resistant Depression (GSRD) study. Anhedonia was assessed through the Montgomery-Åsberg Depression Rating Scale anhedonia item "inability to feel". Clinical and demographic features were then analyzed.

Results: The presence of anhedonia related to a distinct demographical (living alone) and clinical profile (thyroid diseases, diabetes, suicide risk, high number of previous depressive episodes, more severe MDD and more frequent inpatients status). Furthermore, anhedonia was associated with non-response to treatment and treatment resistance, even after adjusting for confounding variables.

Conclusion: Our findings support the role of anhedonia as a modulating feature of MDD, being associated with a more severe depression profile. Moreover, anhedonic features are independent predictors of poor treatment response.

查看原文本刊更多论文

失乐症与特定的抑郁特征和抗抑郁药的不良反应有关。

背景：重度抑郁障碍（MDD）中的失乐症特征与较差的病程和预后有关，并可能预示着对治疗的不反应。然而，目前仍缺乏关于重度抑郁症患者厌世特征的详细临床资料：从欧洲多中心抗药性抑郁症研究小组（GSRD）的横断面研究中选取了1294名MDD患者。厌世情绪通过蒙哥马利-奥斯伯格抑郁量表厌世情绪项目 "无法感受 "进行评估。然后对临床和人口统计学特征进行了分析：结果：失乐症的存在与独特的人口统计学特征（独居）和临床特征（甲状腺疾病、糖尿病、自杀风险、既往抑郁发作次数多、更严重的 MDD 和更频繁的住院状态）有关。此外，即使在调整了混杂变量后，失乐症仍与治疗无反应和治疗抵抗有关：我们的研究结果表明，失乐症是多发性抑郁症的一种调节特征，与更严重的抑郁症特征相关。此外，失乐症特征是治疗反应不佳的独立预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Neuropsychopharmacology 医学-精神病学

CiteScore

8.40

自引率

2.10%

发文量

230

审稿时长

4-8 weeks

期刊介绍： The central focus of the journal is on research that advances understanding of existing and new neuropsychopharmacological agents including their mode of action and clinical application or provides insights into the biological basis of psychiatric disorders and thereby advances their pharmacological treatment. Such research may derive from the full spectrum of biological and psychological fields of inquiry encompassing classical and novel techniques in neuropsychopharmacology as well as strategies such as neuroimaging, genetics, psychoneuroendocrinology and neuropsychology.